Male breast cancer in Cowden syndrome patients with germline PTEN mutations

James D Fackenthal, Deborah J Marsh, Anne-Louise Richardson, Shelly A Cummings, Charis Eng, Bruce G Robinson, Olufunmilayo I Olopade

Abstract
Cowden syndrome (CS) (OMIM 158350) is a multiple hamartoma syndrome associated with germline mutations in the PTEN tumour suppressor gene. While CS is characterised most commonly by non-cancerous lesions (mucocutaneous trichilemmomas, acral and palmpoplantar keratoses, and papillomatous papules), it is also associated with an increased susceptibility to breast cancer (in females) and thyroid cancer, as well as non-cancerous conditions of the breast and thyroid. Here we report two cases of male breast cancer occurring in patients with classical CS phenotypes and germline PTEN mutations. The first subject was diagnosed with CS indicated primarily by mucocutaneous papillomatosis, facial trichilemmomas, and macrocephaly with frontal bossing at the age of 31 years. He developed breast cancer at 41 years and subsequently died of the disease. A PTEN mutation, c.802delG, was identified in this subject, yet none of his family members showed evidence of a CS phenotype, suggesting that this PTEN mutation may be a de novo occurrence. The second subject had a CS phenotype including multiple trichilemmomas and thyroid adenoma, developed male breast cancer at 43 years, and died of the disease at 57 years. He was a carrier of a PTEN mutation c.347-351delACAAT that cosegregated with the CS phenotype in affected family members. These two cases of male breast cancer associated with germline PTEN mutations and the CS phenotype suggest that CS may be associated with an increased risk of early onset male as well as female breast cancer.

Keywords: PTEN; male breast cancer; Cowden syndrome

Cowden syndrome (CS) is an autosomal dominant cancer susceptibility syndrome characterised by multiple hamartomas. While CS is generally considered a rare condition, it is associated with highly variable, subtle, and protein symptoms and signs, suggesting that it may be underdiagnosed and under-reported. CS presentation usually occurs in patients in their twenties and is most commonly indicated by mucocutaneous lesions including trichilemmomas, acral and palmpoplantar keratoses, and verrucoid or papillomatous papules. Other common features include gastrointestinal hamartomas, neurological disorders including macrocephaly and mental retardation, and genitourinary abnormalities including tumours and malformations.

The most common cancers associated with CS are breast (in females) and thyroid carcinomas. Women in CS families have a lifetime risk of developing breast cancer of 25-50%, and an average age of diagnosis 10 years younger than sporadic breast cancer patients. As with other hereditary breast cancers, CS associated breast cancers are also more likely than sporadic breast cancers to be multifocal and bilateral in origin. Thyroid cancer occurs in about 3-10% of CS patients, and these cancers are predominantly follicular carcinomas. In addition to the hallmark breast and thyroid cancers, malignancies in other tissues have also been reported in CS patients, including glioblastomas, mucocutaneous carcinomas, non-small cell carcinomas of the lung, and various gastrointestinal and genitourinary carcinomas, as reviewed by Eng and Parsons. CS is associated with germline mutations in the tumour suppressor gene PTEN (phosphatase and tensin homologue mutated on chromosome ten; also known as MMAC1 or TEP1). PTEN mutations are found in 13-81% of CS families and the PTEN locus is associated with loss of heterozygosity (LOH) in a subset of CS tumours, depending on ascertainment criteria. The PTEN gene encodes a lipid phosphatase that dephosphorylates phosphatidylinositol 3,4 diphosphate (PtdIns(3,4)P2) and phosphatidylinositol 3,4,5 triphosphate (PtdIns(3,4,5)P3) to PtdIns(4)P and PtdIns(4,5)P2 respectively. This lipid phosphatase activity participates in regulating the phosphoinositide 3-kinase (PI3K) regulatory network. Thus, while it is not clear which of the many potential targets of the PTEN phosphatase are most relevant to tumour suppression, its involvement in PI3K regulatory network suggests that it may play a role in both inhibiting cell cycle progression and promoting apoptosis.

Since PTEN was characterised as a tumour suppressor, PTEN mutations have been reported in a number of syndromes other than CS. For example, germline mutations in PTEN are associated with 50-60% of cases of Bannayan-Riley-Ruvalcaba (BRR) syndrome, a multiple hamartoma syndrome showing clinical overlap with CS. Somatic PTEN mutations have been found at high frequencies in sporadic glioblastomas and endometrial and prostate cancers and at lower frequencies in...
cancers of the breast, kidney, thyroid, and colon. PTEN is now considered one of the most frequently mutated genes in human cancers and may therefore represent a critical pathway required for tumour suppression in a variety of tissues. In this study, we report a case of male breast cancer in a subject with a novel germline PTEN mutation and associated Cowden features and further investigate a second Cowden family with male breast cancer.

These observations suggest that PTEN may play a role in tumour suppression in both male and female breast epithelium.

Materials and methods

Family 97-80 was ascertained through the Cancer Risk Clinic at the University of Chicago, USA, and family CDst was ascertained at the Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia. All subjects tested signed informed consent approved by the respective Institutional Review Boards.

Genomic DNA was extracted from peripheral blood using standard protocols. Screening of the PTEN gene for point mutations, deletions, insertions, or small rearrangements was performed by denaturing gradient gel electrophoresis (DGGE) as previously described. PCR products showing an electrophoretic DGGE variant pattern were reamplified from the original genomic DNA, gel isolated, and purified using the Wizard PCR Prep DNA Purification System (Promega, Madison, WI). Purified PCR products were directly sequenced using the ABI Prism Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer, Norwalk, CT). The cycle sequenced products were electrophoresed on 6% Long Ranger gels (FMC Bioproducts, Rockland, ME) and analysed on an Applied Biosystems model 373A automated DNA sequencer (Perkin-Elmer).

Restriction digestion of PCR products was performed under the manufacturer’s recommendations (New England Biolabs, Beverly, MA).

Results

Family 97-80 is a 57 member, four generation kindred with a single affected subject, III.19, a 41 year old male, the youngest of a sibship of 11. He was diagnosed with CS at the age of 31 years when he presented with mucocutaneous papillomatosis, multiple facial trichilemmomas, and severe clubbing of the fingers.

Figure 1 Cowden syndrome in family member III.19. Note the mucocutaneous papillomatosis, facial trichilemmomas, and severe clubbing of the fingers.
expressive) and would be expected to occur multiple times within a family. However, there were no other reports of neurofibromatosis in this family. It is therefore intriguing to speculate whether the reported neurofibromatosis in this family is associated with CS as are other disorders of the nervous system in this syndrome.

II.2 was a 72 year old female with invasive ductal carcinoma of the breast, histological grade 2 and ER(+). Two of 18 axillary lymph nodes had shown metastasis. She also had endometrial carcinoma. A thyroidectomy had been performed at the age of 32 years from which no records were available. Patient II.3, a 65 year old female, was diagnosed with thyroid adenoma but has no other features of CS and is currently alive without cancer. Patient III.1 was diagnosed with breast cancer in her thirties and died of metastatic disease. Family member I.1 had thyroid cancer and died in her fifties of a cerebral haemorrhage.

Sequence analysis of the proband, II.5, showed that the PTEN mutation associated with CS in this family is c.347-351delACAAT. This mutation creates an NsiI restriction site that can be used for rapid detection in at risk family members using a PCR assay (fig 3). This deletion occurs in exon 5 upstream of the PTPase core motif, and is predicted to lead to premature truncation of the protein. Four additional family members were screened by PCR and restriction analysis: II.4 was found to share the same mutation as the proband.

---

**Figure 2** Pedigrees of families with CS and male breast cancer. Affected family members are represented by solid circles (females) or squares (males). Diamonds indicate gender unknown. Hatched circles indicate possible phenocopies. Half circles represent unconfirmed cancer. Numbers within symbols indicate multiple sibs, numbered as indicated above the symbols. +/- indicates that the subject is a carrier of a germline PTEN mutation. -/- indicates that the subject is wild type. Probands with CS are identified by an arrow. (A) Pedigree 97-80. The proband, III.19, was diagnosed with CS at 31 years and breast cancer at 41 years. He carries the germline PTEN c.802delG mutation. (B) Pedigree CDst. The proband, II.5, was diagnosed with breast cancer at 43 years and CS at 47. II.5 and II.4 were shown to be carriers of the PTEN germline mutation c.347-351delACAAT.
ised (II.3, III.14, III.15) subjects in pedigree CDst. The NsiI restriction site is created in those carrying the c.347-351delACAAT germline PTEN mutation. Clinical presentations of male breast cancer.50 Clinical presentations of male breast cancer have a 14-50 fold increased risk of developing breast cancer in females (60 median age of onset in males is later than in female breast cancer,44 depending upon geographical location. In the USA, approximately 1000 males are diagnosed with breast cancer each year.45 Outside the USA and Europe, Japan has the lowest incidence rate (0.6 cases of male breast cancer per 100 000 men),46 while some African nations have higher frequencies. In Zambia, for example, male breast cancer accounts for 15% of all breast cancer cases.47 The risk of male breast cancer can increase in cases of increased levels of oestrogen or decreased levels of androgen, such as in cases of testicular injury48 or cirrhosis of the liver, which is associated with increased levels of oestrogen.49 Men with Klinefelter’s syndrome have a 14-50 fold increased risk of developing male breast cancer.50 Clinical presentations of male and female breast cancers are similar, but median age of onset in males is later than in females (60 v 53 years) and tumours in male breast cancers are generally of higher grade.51–53 Reasons include the low frequency of male breast cancer in the general population, the young age at diagnoses in these two cases compared to the general population, the presence of other CS manifestations in these two men with breast cancer, and, at least in family CDst, segregation of the germline PTEN mutation in all affected subjects.

To our knowledge, there has been only one previous report of a possible male breast cancer case associated with a PTEN mutation in a CS family. This subject’s family showed characteristic cases of skin and uterine abnormalities, along with myomatosis, goitre, and macrocephaly. It was not clear from this study whether the reported male breast involvement was malignant or benign.54 Thus, germline mutation of BRCA2, rarely BRCA1 and MLH1, and now PTEN would appear to be associated with the development of both male and female breast cancer. Both men in this report died of metastatic breast cancer. We believe that males with PTEN mutations may have an increased risk for breast cancer and clinicians taking care of CS patients should now become aware of this risk. Further studies to identify a putative role for PTEN mutations in a larger male breast cancer cohort are continuing.
PTEN mutations in male breast cancer

We are very grateful to the patients who participated in this study. This study was partially supported by grants from the Department of Defense (DAMD17-99-1-9123), the Falk Medical Research Trust (to OH), the NCCR (MGR B00855) and CA14599-24 to the University of Chicago Clinical Research Center and Comprehensive Cancer Center, the American Cancer Society (RPG98-211-01CCE to CE), and the National Cancer Institute (P30CA16568 to The Ohio State University Comprehensive Cancer Center).


